BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32118719)

  • 1. The significance of arginase-1 expression in the diagnosis of liver cancer: A protocol for a systematic review.
    Wang X; Xu Y; Wang R; Dai N; Zhang W; Li F
    Medicine (Baltimore); 2020 Feb; 99(9):e19159. PubMed ID: 32118719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.
    Labib OH; Harb OA; Khalil OH; Baiomy TA; Gertallah LM; Ahmed RZ
    J Gastrointest Cancer; 2020 Mar; 51(1):88-101. PubMed ID: 30784016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
    Li J; Wei L
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of arginase-1, keratin (K) 8 and K18 in combined hepatocellular-cholangiocarcinoma, subtypes with stem-cell features, intermediate-cell type.
    Akiba J; Nakashima O; Hattori S; Naito Y; Kusano H; Kondo R; Nakayama M; Tanikawa K; Todoroki K; Umeno Y; Nakamura K; Sanada S; Yamaguchi R; Ogasawara S; Yano H
    J Clin Pathol; 2016 Oct; 69(10):846-51. PubMed ID: 26969740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Value of Arginase-1 and Glypican-3 in Differential Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Carcinoma of Liver.
    Geramizadeh B; Seirfar N
    Hepat Mon; 2015 Jul; 15(7):e30336. PubMed ID: 26300935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
    Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
    Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
    Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
    Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of arginase-1 expression in distinguishing hepatocellular carcinoma from non-hepatocellular tumors].
    Sang W; Gulinar A; Wang CH; Sheng WQ; Maiweilidan Y; Zhang W
    Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):538-42. PubMed ID: 24246920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.
    Lamps LW; Folpe AL
    Adv Anat Pathol; 2003 Jan; 10(1):39-43. PubMed ID: 12502967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.
    Proca DM; Niemann TH; Porcell AI; DeYoung BR
    Appl Immunohistochem Mol Morphol; 2000 Jun; 8(2):120-5. PubMed ID: 10937059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls.
    Geramizadeh B; Boub R; Rahsaz M
    Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
    J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
    Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
    Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of blood-based liquid biopsies in hepatocellular carcinoma: A protocol for systematic review and meta-analysis.
    Zhang T; Yin M; Wang L; Cao W; Zhong S
    Medicine (Baltimore); 2020 Oct; 99(41):e22594. PubMed ID: 33031312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vivo proton magnetic resonance spectroscopy of hepatocellular carcinoma and cholangiocarcinoma].
    Dong AS; Tian JM; Lu JP; Zuo CJ; Wang L; Wang J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Apr; 31(2):151-4. PubMed ID: 19507591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
    Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alanine-glyoxylate aminotransferase 1 (AGXT1) is a novel marker for hepatocellular carcinomas.
    Zhao CL; Hui Y; Wang LJ; Yang D; Yakirevich E; Mangray S; Huang CK; Lu S
    Hum Pathol; 2018 Oct; 80():76-81. PubMed ID: 29883780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of incidental/misdiagnosed intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma on the outcomes of liver transplantation: an institutional case series and literature review.
    Gupta R; Togashi J; Akamatsu N; Sakamoto Y; Kokudo N
    Surg Today; 2017 Aug; 47(8):908-917. PubMed ID: 28124125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
    Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.